Protease mutation M89I/V is linked to therapy failure in patients infected with the HIV-1 non-B subtypes C, F or G

Objective: To investigate whether and how mutations at position 89 of HIV-1 protease were associated with protease inhibitor (PI) failure, and what is the impact of the HIV-1 subtype. Methods: In a database containing pol nucleotide sequences and treatment history, the correlation between PI experience and mutations at codon 89 was determined separately for subtype B and several non-B subtypes. A Bayesian network model was used to map the resistance pathways in which M891/V is involved for subtype G. The phenotypic effect of M891/V for several Pis was also measured. Results: The analysis showed that for the subtypes C, F and G in which the wild-type codon at 89 was M compared to L for subtype B, M891/V was significantly more frequently observed in PI-treated patients displaying major resistance mutations to Pis than in drug-naive patients. M891/V was strongly associated with PI resistance mutations at codons 71, 74 and 90. Phenotypically, M891/V alone did not confer a reduced susceptibility to Pls. However, when combined with L90M, a significantly reduced susceptibility to nelfinavir was observed (P < 0.05) in comparison with strains with L90M alone. Conclusions: The results of the present study show that M891/V is associated with PI experience in subtypes C, F and G but not in subtype B. M891/V should be considered a secondary PI mutation with an important effect on nelfinavir susceptibility in the presence of L90M. (c) 2005 Lippincott Williams & Wilkins